Mapping cellular heterogeneity and dynamic interactions in pancreatic cancer

Area of Science:

• Oncology
• Genomics
• Biotechnology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is characterized by high mortality and aggressive progression.
• Intra-tumoral heterogeneity (ITH) significantly contributes to PDAC's severity and treatment resistance.
• Understanding PDAC's ITH is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To review the application of single-cell RNA sequencing (scRNA-seq) in dissecting PDAC's intra-tumoral heterogeneity.
• To provide insights into PDAC microenvironment, cellular diversity, and molecular mechanisms driving heterogeneity.
• To highlight scRNA-seq's role in identifying novel biomarkers and therapeutic vulnerabilities in PDAC.

Main Methods:

• Review of studies utilizing single-cell RNA sequencing (scRNA-seq) for PDAC research.
• Discussion of scRNA-seq sample and library preparation, data analysis workflows, and associated challenges.
• Exploration of computational approaches for analyzing scRNA-seq data in PDAC.

Main Results:

• scRNA-seq enables identification of dynamic cell subset transformations and microenvironment modulation in PDAC.
• The technology aids in characterizing cancer stem cells, identifying prognostic gene markers (e.g., MMP1, S100A2), and revealing therapeutic vulnerabilities.
• scRNA-seq facilitates the characterization of PDAC subtypes and evaluation of interventions like radiofrequency ablation.

Conclusions:

• scRNA-seq is a powerful tool for understanding PDAC heterogeneity, offering insights into cellular plasticity and therapeutic targets.
• Biomarker discovery and characterization of PDAC subtypes through scRNA-seq can guide personalized treatment approaches.
• Combined therapeutic strategies, including immunotherapy and targeted inhibitors, show promise in overcoming PDAC resistance.